LUPIN

September 27, 2013

The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sirs,

Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.

Enclosed is a press release as regards receipt of final USFDA approval for the Company's Oral Contraceptive Vyfemla ™ Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4 mg/0.035 mg) to market a generic version of Warner Chilcott Company, LLC.'s Ovcon® 35 Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg).

The above may be considered as a disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: a/a.